During any appeal procedure, shares of the business’s common stock would continue steadily to trade on the NASDAQ Capital Market. The trial is normally a randomized, dual placebo and blind controlled research. It aims to evaluate the safety and effects of a two-week treatment with AZP-531 on food-related behavior and on weight in up to 40 patients with Prader-Willi syndrome. The multicenter trial will be conducted in several Europe. As of today sites are open for recruitment in France and Spain. Results are likely to be available by mid-2016. Prader-Willi syndrome can be a uncommon genetic metabolic syndrome, seen as a hyperphagia, an extreme eating behavior, and severe obesity. Unlike common obesity and type 2 diabetes, Prader-Willi syndrome is associated with elevated blood levels of acylated ghrelin, a hormone with solid stimulating effect on appetite.That is apparently a significant eureka for these researchers, who are just now starting to suspect that there are in fact links between cancers and diet. Of course, this is old news to nutritionists and naturopathic physicians, who have always been urging patients in order to avoid the intake of refined carbohydrates and specifically refined white sugar. Not only is white sugar recognized to cause dietary deficiencies and suppress disease fighting capability and brain function, in addition, it promotes both diabetes and weight problems. Now we are able to officially add cancer compared to that list, thanks to this extensive research. The known truth is, refined white sugars is one of the most unhealthy meals ingredients you can put into the body.